Latest stories on TLSI
TLSI Maintained by Canaccord Genuity -- Price Target Lowered to $4.00
GuruFocus38 · neutralanalyst
TLSI Maintains Buy Rating -- Price Target Lowered to $10.00 by HC Wainwright
GuruFocus42 · neutralanalyst
TriSalus Life Sciences price target lowered to $4 from $7 at Canaccord
The Fly34 · bearishanalyst
TriSalus Life Sciences price target lowered to $6 from $8 at Lake Street
The Fly34 · bearishanalyst
Trisalus Life Sciences Price Target Lowered To 10 From 12 At H C Wainwright
The Fly34 · bearishanalyst
TriSalus: 3 Key Takeaways for Long-Term Investors
The Motley Fool44 · neutralgeneral
Q3 2026 TriSalus Life Sciences Inc Earnings Call Transcript
GuruFocus50 · neutralearnings
TriSalus (TLSI) Q3 2026 Earnings Call Transcript
The Motley Fool38 · neutralearnings
TriSalus stock price target lowered to $4 by Canaccord on guidance reset
Investing.com Analyst Ratings34 · bearishanalyst
Trisalus outlines $46M-$48M 2026 revenue outlook as TriNav Advance clearance supports 2027 growth drivers
Seeking Alpha42 · neutralearnings
TriSalus Life Sciences, Inc. (TLSI) Q3 2026 Earnings Call Transcript
Seeking Alpha50 · neutralearnings
TriSalus Shares Fall After Outlook Cut
MarketWatch34 · bearishanalyst
TriSalus Life Sciences Reports 11.3% Q3 Revenue Growth to $12.9 Million, Revises 2026 Guidance
InvestorsHub64 · neutralearnings
TriSalus Life Sciences, Inc. 2026 Q3 - Results - Earnings Call Presentation
Seeking Alpha50 · neutralearnings
TriSalus Life Sciences misses top-line and bottom-line estimates; updates FY26 outlook
Seeking Alpha34 · bearishearnings
TriSalus Life Sciences, Inc. (TLSIW) files 8-K
SEC 8-K50 · neutralgeneral
TriSalus Life Sciences Reports Third Quarter 2026 Results
StockTitan50 · neutralearnings
TriSalus Life Sciences to Participate in the Canaccord Genuity MedTech, Diagnostics, and Digital Health and Services Forum
StockTitan53 · neutralproduct/pr
TriSalus Life Sciences to Host Third Quarter 2026 Financial Results Conference Call
StockTitan50 · neutralgeneral
TriSalus Life Sciences Shares Rise 15.6% After FDA Clearance for TriNav Advance
InvestorsHub68 · bullishproduct/pr
H.C. Wainwright raises TriSalus stock price target on FDA approval
Investing.com Analyst Ratings67 · bullishanalyst
TriSalus Wins FDA 510(k) Clearance for TriNav Advance, Adding Small-Vessel Access to Its PEDD Portfolio
September 23, 2026
MarketChameleon71 · bullishproduct/pr
TriSalus Life Sciences price target raised to $12 from $11 at H.C. Wainwright
The Fly63 · neutralanalyst
TriSalus jumps 16% after FDA clears TriNav Advance device
Seeking Alpha73 · bullishproduct/pr
Why is TriSalus Life Sciences stock surging today?
Investing.com Markets50 · neutralgeneral